Maze Therapeutics (NASDAQ:MAZE) Shares Up 6.4% – Should You Buy?

Maze Therapeutics, Inc. (NASDAQ:MAZE)’s stock price rose 6.4% on Monday . The stock traded as high as $12.88 and last traded at $12.77. Approximately 27,430 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 270,449 shares. The stock had previously closed at $12.00.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Leerink Partnrs upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 25th. Guggenheim started coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set a “buy” rating and a $19.00 price objective for the company. Leerink Partners assumed coverage on Maze Therapeutics in a report on Tuesday, February 25th. They issued an “outperform” rating and a $28.00 target price on the stock. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 25th. Finally, JPMorgan Chase & Co. began coverage on Maze Therapeutics in a research report on Tuesday, February 25th. They set an “overweight” rating and a $30.00 price objective for the company. Three equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $25.67.

Maze Therapeutics Stock Performance

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.